Showing 1 - 7 of 7
Estimating medical care productivity is a central economic challenge. This paper develops a satellite account for the US health sector that appropriately measures health care productivity and applies that to the elderly population between 1999 and 2012. The central output of the satellite...
Persistent link: https://www.econbiz.de/10012481152
Mortality rates in the US fell more rapidly during the late 19th and early 20th Centuries than any other period in American history. This decline coincided with an epidemiological transition and the disappearance of a mortality "penalty" associated with living in urban areas. There is little...
Persistent link: https://www.econbiz.de/10012468182
The conventional wisdom in health economics is that idiosyncratic features of the healthcare sector leave little scope for market forces to allocate consumers to higher performance producers. However, we find robust evidence across a variety of conditions and performance measures that higher...
Persistent link: https://www.econbiz.de/10012457066
Adverse behavioral risk factors contribute to a large share of deaths. We examine the effects on life expectancy (LE) and quality-adjusted life expectancy (QALE) of changes in six major behavioral risk factors over the 1960-2010 period: smoking, obesity, heavy alcohol use, and unsafe use of...
Persistent link: https://www.econbiz.de/10012458034
The conventional wisdom in health economics is that large differences in average productivity across hospitals are the result of idiosyncratic, institutional features of the healthcare sector which dull the role of market forces. Strikingly, however, we find that productivity dispersion in heart...
Persistent link: https://www.econbiz.de/10012459463
The potential of artificial intelligence (AI) to simplify existing healthcare processes and create new, more efficient ones is a major topic of discussion in the industry. Yet healthcare lags other industries in AI adoption. In this paper, we estimate that wider adoption of AI could lead to...
Persistent link: https://www.econbiz.de/10013537751
Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this...
Persistent link: https://www.econbiz.de/10013477204